Taysha Gene Therapies (TSHA.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov12

Taysha Announces Progress in TSHA-102 Gene Therapy Candidate for Rett Syndrome Treatment

19:49

Nov5

Analysts Give Taysha Gene Therapies Strong Buy Rating

13:02

Nov4

Taysha Gene Therapies released FY2025 9 Months Earnings on November 4 During-Market EST, Actual Revenue: USD 4.288 M, Actual EPS: USD -0.2627

21:00

Taysha Gene Therapies released FY2025 Q3 earnings on November 4 During-Market EST, actual revenue USD 0 (forecast USD 1.381 M), actual EPS USD -0.0926 (forecast USD -0.0884)

21:00

Taysha Gene Therapies revises sales agreement and regains full rights to Rett syndrome project

12:36

Taysha Gene Therapies Reports Q3 Operational Expenses at $34.024 Million, EPS at -$0.09

12:00

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -32.73 M, EPS -0.0926

Aug12

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.986 M, Net Income -26.88 M, EPS -0.0902

May15

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 2.302 M, Net Income -21.53 M, EPS -0.0799

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change